238 related articles for article (PubMed ID: 12886957)
1. Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy.
Chiang SR; Chuang YC
J Microbiol Immunol Infect; 2003 Jun; 36(2):81-8. PubMed ID: 12886957
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antimicrobial effect of cefotaxime and minocycline on proinflammatory cytokine levels in a murine model of Vibrio vulnificus infection.
Chiang SR; Tang HJ; Chang PC; Cheng KC; Ko WC; Chen CH; Chuang YC
J Microbiol Immunol Infect; 2007 Apr; 40(2):123-33. PubMed ID: 17446960
[TBL] [Abstract][Full Text] [Related]
3. Vibrio vulnificus infection: diagnosis and treatment.
Bross MH; Soch K; Morales R; Mitchell RB
Am Fam Physician; 2007 Aug; 76(4):539-44. PubMed ID: 17853628
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus.
Tang HJ; Chen CC; Lai CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
J Microbiol Immunol Infect; 2018 Feb; 51(1):76-81. PubMed ID: 27260781
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection.
Horseman MA; Surani S
Int J Infect Dis; 2011 Mar; 15(3):e157-66. PubMed ID: 21177133
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.
Tang HJ; Chang MC; Ko WC; Huang KY; Lee CL; Chuang YC
Antimicrob Agents Chemother; 2002 Nov; 46(11):3580-4. PubMed ID: 12384368
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and antibiotics in Vibrio vulnificus septicemia.
Liu JW; Lee IK; Tang HJ; Ko WC; Lee HC; Liu YC; Hsueh PR; Chuang YC
Arch Intern Med; 2006 Oct; 166(19):2117-23. PubMed ID: 17060542
[TBL] [Abstract][Full Text] [Related]
8. Cefazolin plus minocycline against a clinical isolate of Vibrio vulnificus: in vitro and animal studies.
Tang HJ; Ko WC; Chuang YC; Chen CC; Chiang SR
Jpn J Infect Dis; 2010 Jan; 63(1):16-8. PubMed ID: 20093756
[TBL] [Abstract][Full Text] [Related]
9. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.
Chuang YC; Ko WC; Wang ST; Liu JW; Kuo CF; Wu JJ; Huang KY
Antimicrob Agents Chemother; 1998 Jun; 42(6):1319-22. PubMed ID: 9624467
[TBL] [Abstract][Full Text] [Related]
10. Use of a marker plasmid to examine differential rates of growth and death between clinical and environmental strains of Vibrio vulnificus in experimentally infected mice.
Starks AM; Bourdage KL; Thiaville PC; Gulig PA
Mol Microbiol; 2006 Jul; 61(2):310-23. PubMed ID: 16856938
[TBL] [Abstract][Full Text] [Related]
11. [Vibrio vulnificus septicemia transmitted through a wound caused by a crustacea].
Renault PA; Vargas C; Tachet A; Tattevin P; Najman A; Quilici ML; Fournier JM
Presse Med; 2003 Jun; 32(22):1028-30. PubMed ID: 12876519
[TBL] [Abstract][Full Text] [Related]
12. [Vibrio vulnificus septicemia in Spain].
García Cuevas M; Collazos González J; Martínez Gutiérrez E; Mayo Suárez J
An Med Interna; 1998 Sep; 15(9):485-6. PubMed ID: 10079541
[TBL] [Abstract][Full Text] [Related]
13. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.
Kim DM; Lym Y; Jang SJ; Han H; Kim YG; Chung CH; Hong SP
Antimicrob Agents Chemother; 2005 Aug; 49(8):3489-91. PubMed ID: 16048966
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase A as a potent virulence factor of Vibrio vulnificus.
Koo BS; Lee JH; Kim SC; Yoon HY; Kim KA; Kwon KB; Kim HR; Park JW; Park BH
Int J Mol Med; 2007 Dec; 20(6):913-8. PubMed ID: 17982702
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic therapy for necrotizing fasciitis caused by Vibrio vulnificus: retrospective analysis of an 8 year period.
Chen SC; Lee YT; Tsai SJ; Chan KS; Chao WN; Wang PH; Lin DB; Chen CC; Lee MC
J Antimicrob Chemother; 2012 Feb; 67(2):488-93. PubMed ID: 22117030
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.
Jang HC; Choi SM; Kim HK; Kim SE; Kang SJ; Park KH; Ryu PY; Lee TH; Kim YR; Rhee JH; Jung SI; Choy HE
PLoS One; 2014; 9(6):e101118. PubMed ID: 24978586
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of Vibrio vulnificus isolated from cockles and patients in Thailand.
Mala W; Chomvarin C; Alam M; Rashed SM; Faksri K; Angkititrakul S
Southeast Asian J Trop Med Public Health; 2014 Jan; 45(1):103-12. PubMed ID: 24964659
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein protects Vibrio vulnificus-induced lethality through blocking lipopolysaccharide action.
Park KH; Kim JS; Lee YR; Moon YJ; Hur H; Choi YH; Kim CH; Kim UH; Song EK; Yoo WH; Lee CS; Kim BS; Lee SH; Ryu PY; Han MK
Exp Mol Med; 2007 Oct; 39(5):673-8. PubMed ID: 18059143
[TBL] [Abstract][Full Text] [Related]
19.
Kim SE; Kim HK; Choi SM; Yu Y; Kim UJ; Darboe KS; Kang SJ; Park KH; Kang G; Kim YR; Rhee JH; Jung SI; Jang HC
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332060
[TBL] [Abstract][Full Text] [Related]
20. Varied clinical presentations of Vibrio vulnificus infections: a report of four unusual cases and review of the literature.
Ulusarac O; Carter E
South Med J; 2004 Feb; 97(2):163-8. PubMed ID: 14982266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
